Advances in the treatment of glioblastoma multiforme
Glioblastoma multiforme is the most common central nervous system (CNS) primary tumor in men. Its incidence in Europe lies between 3 to 4 cases per 100,000 inhabitants and it represents 25% of all the CNS tumors and 50% of the primary tumors. Less than 3% of all patients diagnosed with glioblastoma...
| Autor Principal: | Jaramillo, Sonia; Pontificia Universidad Javerian |
|---|---|
| Otros Autores: | Osorio, Walter; Pontificia Universidad Javeriana, Espitia, Juan Carlos; Pontificia Universidad Javeriana |
| Formato: | info:eu-repo/semantics/article |
| Idioma: | spa |
| Publicado: |
Pontificia Universidad Javeriana
2010
|
| Materias: | |
| Acceso en línea: |
http://revistas.javeriana.edu.co/index.php/vnimedica/article/view/15985 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: |
Glioblastoma multiforme is the most common central nervous system (CNS) primary tumor in men. Its incidence in Europe lies between 3 to 4 cases per 100,000 inhabitants and it represents 25% of all the CNS tumors and 50% of the primary tumors. Less than 3% of all patients diagnosed with glioblastoma multiforme survive more than 4 years and the average survival is of 6 months. Studies aiming to increase the survival rate, as well as to achieve longer asymptomatic periods are being carried out at present. The main goal of this review is to offer a brief recount on the progress in the treatment of glioblastoma multiforme, focusing on genetic therapy. The consulted literature showed, that there are only two types of mutations capable of defining the prognosis of this disease at this point; one is the presence of O6-methylguanine-DNA methyltransferase protein expression (MGMT) and the 1p/ 19q deletion on which we will emphasize in the course of this document. |
|---|